Interpretation of the standard of Detection and preventive treatment of latent tuberculosis infection in children

doi:10.19982/j.issn.1000-6621.20220426

Abstract

Abstract:

The standard of Detection and preventive treatment of latent tuberculosis infection in children (T/CHATA 015-2021) was published by the Chinese Antituberculosis Association on July 9, 2021. This standard was interpreted from the aspects of screening population, screening methods, diagnostic standards and anti-tuberculosis preventive treatment of latent tuberculosis infection, aiming to further improve the cognition of clinical pediatricians and staff related to tuberculosis diagnosis and treatment on latent tuberculosis infection in children, and standardize the management of latent tuberculosis infection in children.

Key words: Child, Mycobacterium tuberculosis, Infection, Diagnosis, Protective agents

CLC Number:

R52
R725

Wang Zeming, Shen Adong. Interpretation of the standard of Detection and preventive treatment of latent tuberculosis infection in children[J]. Chinese Journal of Antituberculosis, 2023, 45(1): 13-17. doi: 10.19982/j.issn.1000-6621.20220426

References 21

[1]	Houben RM, Dodd PJ. The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. PLoS Med, 2016, 13(10): e1002152. doi:10.1371/journal.pmed.1002152. doi: 10.1371/journal.pmed.1002152. URL
[2]	World Health Organization. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva: World Health Organization, 2018.
[3]	Shah M, Dorman SE. Latent Tuberculosis Infection. N Engl J Med, 2021, 385(24): 2271-2280. doi:10.1056/NEJMcp2108501. doi: 10.1056/NEJMcp2108501. URL
[4]	Martinez L, Shen Y, Mupere E, et al. Transmission of Mycobacterium Tuberculosis in Households and the Community: A Systematic Review and Meta-Analysis. Am J Epidemiol, 2017, 185(12): 1327-1339. doi:10.1093/aje/kwx025. doi: 10.1093/aje/kwx025. URL
[5]	阮巧玲, 黄希田, 刘雪峰, 等. 免疫受损人群的潜伏性结核感染筛查和预防性治疗. 中国防痨杂志, 2017, 39(7): 765-769. doi:10.3969/j.issn.1000-6621.2017.07.020. doi: 10.3969/j.issn.1000-6621.2017.07.020.
[6]	Xie X, Li F, Chen JW, et al. Risk of tuberculosis infection in anti-TNF-α biological therapy: from bench to bedside. J Microbiol Immunol Infect, 2014, 47(4): 268-274. doi:10.1016/j.jmii.2013.03.005. doi: 10.1016/j.jmii.2013.03.005 pmid: 23727394
[7]	Carranza C, Pedraza-Sanchez S, de Oyarzabal-Mendez ED, et al. Diagnosis for Latent Tuberculosis Infection: New Alternatives. Front Immunol, 2020, 11: 2006. doi:10.3389/fimmu.2020.02006. doi: 10.3389/fimmu.2020.02006 pmid: 33013856
[8]	Youssef J, Novosad SA, Winthrop KL. Infection Risk and Safety of Corticosteroid Use. Rheum Dis Clin North Am, 2016, 42(1): 157-176, ix-x. doi:10.1016/j.rdc.2015.08.004. doi: 10.1016/j.rdc.2015.08.004. URL
[9]	Brock I, Weldingh K, Lillebaek T, et al. Comparison of tuberculin skin test and new specific blood test in tuberculosis contacts. Am J Respir Crit Care Med, 2004, 170(1): 65-69. doi:10.1164/rccm.200402-232OC. doi: 10.1164/rccm.200402-232OC. URL
[10]	Böncüogˇlu E, Kıymet E, Şahinkaya Ş, et al. Usefulness of screening tests for diagnosis of latent tuberculosis infection in children. Pediatr Pulmonol, 2021, 56(5): 1114-1120. doi:10.1002/ppul.25173. doi: 10.1002/ppul.25173. URL
[11]	Zenner D, Beer N, Harris RJ, et al. Treatment of Latent Tuberculosis Infection: An Updated Network Meta-analysis. Ann Intern Med, 2017, 167(4): 248-255. doi:10.7326/M17-0609. doi: 10.7326/M17-0609 pmid: 28761946
[12]	World Health Organization. WHO consolidated guidelines on tuberculosis: Module 4: Treatment—Drug-resistant tuberculosis treatment. Geneva: World Health Organization, 2020.
[13]	祁雪, 田建岭, 孙琳, 等. 儿童结核分枝杆菌潜伏感染的筛查和预防性治疗. 中国防痨杂志, 2018, 40(5): 447-454. doi:10.3969/j.issn.1000-6621.2018.05.003. doi: 10.3969/j.issn.1000-6621.2018.05.003.
[14]	Malik AA, Farooq S, Jaswal M, et al. Safety and feasibility of 1 month of daily rifapentine plus isoniazid to prevent tuberculosis in children and adolescents: a prospective cohort study. Lancet Child Adolesc Health, 2021, 5(5): 350-356. doi:10.1016/s2352-4642(21)00052-3. doi: 10.1016/S2352-4642(21)00052-3 pmid: 33770510
[15]	Radtke KK, Hibma JE, Hesseling AC, et al. Pragmatic global dosing recommendations for the 3-month, once-weekly rifa-pentine and isoniazid preventive TB regimen in children. Eur Respir J, 2021, 57(1): 2001756. doi:10.1183/13993003.01756-2020. doi: 10.1183/13993003.01756-2020. URL
[16]	Yang H, Yang Y, Hu ZD, et al. High rate of completion for weekly rifapentine plus isoniazid treatment in Chinese children with latent tuberculosis infection—A single center study. PLoS One, 2021, 16(6): e0253159. doi:10.1371/journal.pone.0253159. doi: 10.1371/journal.pone.0253159.
[17]	Ayieko J, Abuogi L, Simchowitz B, et al. Efficacy of isoniazid prophylactic therapy in prevention of tuberculosis in children: a meta-analysis. BMC Infect Dis, 2014, 14: 91. doi:10.1186/1471-2334-14-91. doi: 10.1186/1471-2334-14-91 pmid: 24555539
[18]	Stagg HR, Zenner D, Harris RJ, et al. Treatment of latent tuberculosis infection: a network meta-analysis. Ann Intern Med, 2014, 161(6): 419-428. doi:10.7326/M14-1019. doi: 10.7326/M14-1019 pmid: 25111745
[19]	Spyridis NP, Spyridis PG, Gelesme A, et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis, 2007, 45(6): 715-722. doi:10.1086/520983. doi: 10.1086/520983. pmid: 17712755
[20]	Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med, 2011, 365(23): 2155-2166. doi:10.1056/NEJMoa1104875. doi: 10.1056/NEJMoa1104875. URL
[21]	Villarino ME, Scott NA, Weis SE, et al. Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid. JAMA Pediatr, 2015, 169(3): 247-255. doi:10.1001/jamapediatrics.2014.3158. doi: 10.1001/jamapediatrics.2014.3158 pmid: 25580725